{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vector&page=13",
    "query": {
      "condition": "Vector",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 687,
    "total_pages": 69,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vector&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vector&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T15:19:20.405Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03882528",
      "title": "Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria,Falciparum"
      ],
      "interventions": [
        {
          "name": "Plasmodium falciparum malaria parasite",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 12,
      "start_date": "2019-03-04",
      "completion_date": "2019-05-16",
      "has_results": true,
      "last_update_posted_date": "2021-03-30",
      "last_synced_at": "2026-10-23T15:19:20.405Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03882528"
    },
    {
      "nct_id": "NCT02639299",
      "title": "Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Malaria"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 1500,
      "start_date": "2016-12-08",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-23T15:19:20.405Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02639299"
    },
    {
      "nct_id": "NCT01984983",
      "title": "Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Venezuelan Equine Encephalitis Virus Infection"
      ],
      "interventions": [
        {
          "name": "Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.9% saline placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Ichor Medical Systems Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 42,
      "start_date": "2013-12",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2015-08-26",
      "last_synced_at": "2026-10-23T15:19:20.405Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01984983"
    },
    {
      "nct_id": "NCT00377416",
      "title": "Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "rAAV2-CB-hAAT Gene Vector",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2004-03",
      "completion_date": "2020-01",
      "has_results": false,
      "last_update_posted_date": "2020-04-10",
      "last_synced_at": "2026-10-23T15:19:20.405Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Worcester, Massachusetts",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00377416"
    },
    {
      "nct_id": "NCT01438112",
      "title": "Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Transitional Cell Carcinoma",
        "Bladder Cancer",
        "Carcinoma in Situ",
        "Carcinoma in Situ Concurrent With Papillary Tumors"
      ],
      "interventions": [
        {
          "name": "CG0070 Adenovirus Vector",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Arm: Quadruple Choice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "CG Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2014-03",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2021-04-14",
      "last_synced_at": "2026-10-23T15:19:20.405Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01438112"
    },
    {
      "nct_id": "NCT04563702",
      "title": "Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "VXA-CoV2-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vaxart",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "54 Years",
        "sex": "ALL",
        "summary": "18 Years to 54 Years"
      },
      "enrollment_count": 35,
      "start_date": "2020-09-21",
      "completion_date": "2021-10-10",
      "has_results": false,
      "last_update_posted_date": "2024-06-21",
      "last_synced_at": "2026-10-23T15:19:20.405Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04563702"
    },
    {
      "nct_id": "NCT05095272",
      "title": "Blood-Stage Plasmodium Vivax Cell Bank",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "HMPBS02-Pv",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 2,
      "start_date": "2022-02-15",
      "completion_date": "2022-09-15",
      "has_results": true,
      "last_update_posted_date": "2023-07-11",
      "last_synced_at": "2026-10-23T15:19:20.405Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05095272"
    },
    {
      "nct_id": "NCT05553639",
      "title": "HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "HB-302/HB-301 Alternating 2-Vector Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hookipa Biotech GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2023-05-23",
      "completion_date": "2024-04-29",
      "has_results": false,
      "last_update_posted_date": "2024-06-12",
      "last_synced_at": "2026-10-23T15:19:20.405Z",
      "location_count": 10,
      "location_summary": "Duarte, California • San Marcos, California • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05553639"
    },
    {
      "nct_id": "NCT02313376",
      "title": "Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "GAP3KO",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 10,
      "start_date": "2014-12",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2015-11-18",
      "last_synced_at": "2026-10-23T15:19:20.405Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02313376"
    },
    {
      "nct_id": "NCT01397227",
      "title": "A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Crucell Holland BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2011-06",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-09-07",
      "last_synced_at": "2026-10-23T15:19:20.405Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01397227"
    }
  ]
}